Pasar al contenido principal

CARACTERIZACION DE LA PERDIDA PROGRESIVA DE VASOS POR ANGIOGENESIS NO PRODUCTIVA, UN NUEVO MECANISMO PATOLOGICO EN LA ENFERMEDAD DE ALZHEIMER

RTI2018-096629-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidate

  • Villadiego, Javier
  • García-Arriaza, Juan
  • Ramírez Lorca, Reposo
  • García-Swinburn, Roberto
  • Cabello-Rivera, Daniel
  • Rosales-Nieves, Alicia E.
  • Álvarez-Vergara, María I.
  • Cala-Fernández, Fernando
  • García-Roldán, Ernesto
  • López-Ogáyar, Juan L.
  • Zamora, Carmen
  • Astorgano, David
  • Albericio, Guillermo
  • Pérez Ramírez, Patricia
  • Muñoz-Cabello, Ana M.
  • Pascual Bravo, Alberto
  • Esteban, Mariano
  • López-Barneo, José
  • Toledo-Aral, Juan José
Vaccines against SARS-CoV-2 have been shown to be safe and effective but their protective efficacy against infection in the brain is yet unclear. Here, in the susceptible transgenic K18-hACE2 mouse model of severe coronavirus disease 2019 (COVID-19), we report a spatiotemporal description of SARS-CoV-2 infection and replication through the brain. SARS-CoV-2 brain replication occurs primarily in neurons, leading to neuronal loss, signs of glial activation and vascular damage in mice infected with SARS-CoV-2. One or two doses of a modified vaccinia virus Ankara (MVA) vector expressing the SARS-CoV-2 spike (S) protein (MVA-CoV2-S) conferred full protection against SARS-CoV-2 cerebral infection, preventing virus replication in all areas of the brain and its associated damage. This protection was maintained even after SARS-CoV-2 reinfection. These findings further support the use of MVA-CoV2-S as a promising vaccine candidate against SARS-CoV-2/COVID-19., We thank the CSIC and the Spanish Ministry of Science and Innovation for continuous support. This research was supported by the Spanish Ministry of Science and Innovation/Spanish Research Agency/10.13039/501100011033 grant nos. PID2019-105995RB-I00 (J.J.T.-A. and J.V.), PID2020-114481RB-I00 (J.G.-A. and M.E.), RTI2018-096629-B-I00 (A.P.) and PID2019-106410RB-I00 (J.L.-B.). Moreover, this research was also funded by Red TerCel ISCIII (no. RD16/0011/0025 to J.J.T.-A.), Consejería de Economía, Conocimiento, Empresas y Universidad US-1380891 (to J.J.T.-A. and J.V.), Consejería de Salud y Familias, Junta de Andalucía grant no. PECOVID-0078-2020 (to R.R.-L. and J.V.), Consejería de Educación y Deporte, Junta de Andalucía grant no. PY20_01312 (to A.P.), Fondo COVID-19 grant no. COV20/00151 (Spanish Health Ministry, Instituto de Salud Carlos III), Fondo Supera COVID-19 (Crue Universidades-Banco Santander) grant and CSIC grant no. 202120E079 (J.G.-A.), CSIC grant no. 2020E84, La CaixaImpulse grant no. CF01-00008 and Ferrovial and MAPFRE donations (to M.E.). Additionally, we received funding from the European Commission-NextGenerationEU, through the CSIC’s Global Health Platform (PTI Salud Global) (to J.G.-A. and M.E.) and the European Research Council (ERC Advanced grant no. PRJ201502629) (to J.L.-B.). J.G.-A. and M.E. also acknowledge financial support from the Spanish State Research Agency (no. AEI/10.13039/501100011033) through the ‘Severo Ochoa’ Programme for Centres of Excellence in R&D (nos. SEV-2013-0347 and SEV-2017-0712). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inactivation of the PHD3-FOXO3 axis blunts the type I interferon response in microglia and ameliorates Alzheimer's disease progression

  • Sánchez García, Manuel A.
  • Lara-Ureña, Nieves
  • March Díaz, Rosana
  • Ortega de San Luis, Clara
  • Quiñones-Cañete, Silvia
  • Mora-Romero, Bella
  • Barba-Reyes, Juan M.
  • Cabello-Rivera, Daniel
  • Romero-Molina, Carmen
  • Heras-Garvin, Antonio
  • Navarro-Garrido, Victoria
  • López-Barneo, José
  • Vizuete, Marisa
  • Vitorica, Javier
  • Muñoz-Cabello, Ana M.
  • Muñoz-Manchado, Ana B.
  • Cokman, Matthew E
  • Rosales-Nieves, Alicia E.
  • Pascual Bravo, Alberto
Microglia respond to Alzheimer’s disease (AD) with varied transcriptional responses. We show that oligomeric Aß (oAß) induces the expression of Hif1a and Egln3 in microglia in vitro, together with the transcription of the type I interferon signature (IFNS) genes in a PHD3-dependent manner. We identify FOXO3 as a repressor of IFNS, whose abundance decreases upon PHD3 induction in response to oAß. In vivo, loss of PHD3 correlates with abrogation of the IFNS and activation of the disease-associated microglia signature, an increase in microglia proximity to Aß plaques and phagocytosis of both Aß and small plaques. PHD3 deficiency mitigated the Aß plaque–associated neuropathology and rescued behavioral deficits of an AD mouse model. Last, we demonstrate that microglial PHD3 overexpression in the absence of Aß pathology is sufficient to induce the IFNS and behavioral alterations. Together, our data strongly indicate that the inactivation of the PHD3-FOXO3 axis controls the microglial IFNS in a cell autonomous manner, improving AD outcome., This work was supported by grants to A.P., J.V., A.M.M.-C., and A.B.M.-M. by MCIN/AEI/10.13039/501100011033 and ERDF/EU, ISCIII (FORT23/00008 to A.P. and PI21/00915 to J.V.), and FEDER (RTI2018-096629-B-100, PID2021-126894OB-I00, PID2019-109046GA-I00, and PID2022-136526OB-I00; and “FEDER Una manera de hacer Europa,” SAF2017-90794-REDT, and PIE13/0004); by the regional Government of Andalucia (“Proyectos de Excelencia” P12-CTS-2138, P20_01312; Biotechnology Plan applied to Health PRTR-C17.I1; FEDER Andalucia 2014-2020, US-1261055) co-funded by CEC, REC_EU, and FEDER funds; and by the “Ayuda de Biomedicina 2018,” Fundación Domingo Martínez; and to M.E.C. by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001501), the UK Medical Research Council (FC001501), and the Wellcome Trust (FC001501). R.M.-D. was the recipient of a “Sara Borrell” fellowship from ISCIII (CD09/0007); M.A.S.-G., N.L.-U., C.O-d.S.L., C.R.-M., and S.Q.-C. were recipients of an FPU fellowship from Spanish Ministry of Education, Culture, and Sport (respectively, FPU13/00530, FPU14/02115, AP2010–1598, FPU16/02050, and FPU22/00974); A.H.-G. was the recipient of an FPI fellowship from Spanish Ministry of Education, Culture, and Sport (BES-2010-033886); and B.M.-R. was the recipient of a “Junta de Andalucía” predoctoral fellowship (2021). A.E.R.-N. was recipient of JdlC-F fellowship from MCIN/AEI/10.13039/501100011033 (FJCI-2015-23708) and “Contrato de Acceso de I+D+i” from VI PPIT—Universidad de Sevilla. A.B.M.-M. was recipient of the RyC program RYC-2017-22594. J.M.B.-R. was recipient of a 2019-FPI fellowship., Peer reviewed